Get the Stockscreener App
49.87
8.73%
-4.77
After Hours:
50.50
0.63
+1.26%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $49.87, with a volume of 6.76M.
It is down -8.73% in the last 24 hours and down -6.15% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$54.64
Open:
$53.16
24h Volume:
6.76M
Relative Volume:
2.81
Market Cap:
$7.82B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
53.05
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
-13.59%
1M Performance:
-6.15%
6M Performance:
-33.52%
1Y Performance:
-36.41%
1-Day Range:
$47.66
$54.56
1-Week Range:
$47.66
$57.74
52-Week Range:
$46.01
$80.95
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
(612) 379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
49.87 | 8.57B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Bio-Techne takes a hit on Exodx sale to Mdxhealth - BioWorld MedTech
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Bio-Techne's Q4 Fiscal 2025 Results Trigger 6.5% Share DeclineNews and Statistics - IndexBox
Why Bio-Techne (TECH) Shares Are Plunging Today - Yahoo Finance
Earnings call transcript: Bio-Techne Q4 2025 beats EPS forecasts - Investing.com
Bio-Techne Q2 2025 Financial Results: Revenue and EPS Surpass ExpectationsNews and Statistics - IndexBox
Bio-Techne Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations - Yahoo Finance
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls - Nasdaq
Bio-Techne Exceeds Forecasts And Refines Its Focus On Growth - Finimize
Bio-Techne Q4 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Bio-Techne Corp (TECH) Q4 Earnings: Revenue Surpasses Estimates at $317M, Adjusted EPS at $0.53, GAAP EPS Misses at ($0.11) - GuruFocus
Bio-Techne earnings beat by $0.03, revenue topped estimates - Investing.com Canada
Bio-techne declares quarterly dividend of $0.08 per share - Investing.com
Bio-Techne Earnings Beat Estimates as Cell Therapy Division Drives Growth, Strategic Divestiture Announced - Stock Titan
Dividend Alert: Bio-Techne Sets $0.08 Per Share Payout, Reveals August Payment Timeline - Stock Titan
Bio-techne to sell exosome diagnostics business to mdxhealth By Investing.com - Investing.com South Africa
Bio-techne to sell exosome diagnostics business to mdxhealth - Investing.com
Bio-Techne Sells Prostate Cancer Test Business to Strengthen Core Operations: Strategic Shift Revealed - Stock Titan
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne - The Manila Times
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? - MSN
Stock Analysis | Bio-Techne OutlookWeak Technicals but Strong Fundamentals - AInvest
Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow - ca.finance.yahoo.com
Why is Bio Techne Corporation stock attracting strong analyst attentionStay informed with daily expert analysis - Jammu Links News
What drives Bio Techne Corporation stock priceExponential wealth increase - Jammu Links News
When is Bio Techne Corporation stock expected to show significant growthGain insights from top financial experts - Jammu Links News
Is Bio Techne Corporation stock overvalued or undervaluedMassive profits - Jammu Links News
How strong is Bio Techne Corporation company’s balance sheetMaximize your returns with portfolio optimization - Jammu Links News
Bio Techne Corporation Shows Risk Reward Favoring UpsideAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Is it the right time to buy Bio Techne Corporation stockAI Powered Growth Plan For 2025 - Jammu Links News
Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending - ca.finance.yahoo.com
Bio-Techne Corporation (TECH) Slid on Rise in Investors’ Concerns - Yahoo Finance
Promising Long-Term Growth for Bio-Techne Amidst Current Challenges: A Buy Recommendation by Kyle Boucher - TipRanks
Will Bio Techne Corporation stock benefit from interest rate changesLow Risk High Return Opportunities Identified - beatles.ru
Momentum Screeners Rank Bio Techne Corporation in Top 5 TodayReal-Time Trade Insights Spark Market Reactions - metal.it
Why Bio Techne Corporation is moving today Weekly Setup Summary for Risk Controlled Trades - metal.it
How many analysts rate Bio Techne Corporation as a “Buy”Discover the fastest growing stocks today - Jammu Links News
Bio-Techne Corporation (TECH) Gets Initiated With a New Buy Rating at TD Cowen - Insider Monkey
What makes Bio Techne Corporation stock price move sharplyAchieve rapid capital gains with smart investing - Jammu Links News
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH) - Yahoo Finance
Bio-Techne’s Quarterly Earnings Preview: What You Need to Know - MSN
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Bio-Techne Corporation (TECH): A Bull Case Theory - Yahoo Finance
What analysts say about Bio Techne Corporation stockTriple returns potential - jammulinksnews.com
Bio-Techne (TECH) Stock Is Up, What You Need To Know - Yahoo Finance
Bio Techne Corporation Stock Analysis and ForecastFree Investment Community - Autocar Professional
Bio-Techne Corporation shares rise 1.99% after-hours as US stocks close higher. - AInvest
Bio-Techne Corp. stock underperforms Monday when compared to competitors - MarketWatch
Envestnet Asset Management Inc. Sells 66,478 Shares of Bio-Techne Corp (NASDAQ:TECH) - Defense World
Bio-Techne’s Quarterly Earnings Preview: What You Need To Know - Barchart.com
Bio-Techne Schedules Q4 2025 Earnings Call: Full Fiscal Year Results Coming August 6 - Stock Titan
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelderman Kim | Chief Executive Officer |
Jul 22 '25 |
Option Exercise |
44.33 |
48,176 |
2,135,642 |
90,379 |
| Kelderman Kim | Chief Executive Officer |
Jul 15 '25 |
Option Exercise |
44.33 |
36,132 |
1,601,732 |
75,136 |
| Herr Amy E. | Director |
Jun 09 '25 |
Option Exercise |
44.33 |
1,280 |
56,742 |
3,256 |
| Herr Amy E. | Director |
Jun 09 '25 |
Sale |
49.77 |
1,280 |
63,705 |
1,976 |
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):